Difficult-to-treat bowel cancers respond in first study of new drug combination

(ECCO-the European CanCer Organisation) Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news